Meissner, V H;Jahnen, M;Herkommer, K.[Familial prostate cancer and genetic predisposition]..Urologe A.2021.60.5.567-575

Rexer, H.;Retz, M.;Steiner, T..Second or Third-Line-Therapy for inoperable, locally advanced or metastatic Renal Cell Carcinoma.Urologe A.2021.60.6.836-837

Rexer, Heidrun;Retz, Margitta;Steiner, Thomas.Second- or Third-Line Therapy of non-operable, locally advanced or metastatic Renal Cell Carcinoma.Aktuelle Urol.2021.52.05.425-426

Rexer, H.;Retz, M.;Hammerer, P..First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO.Urologe A.2021.60.7.987-988

Rexer, Heidrun;Kuebler, Hubert;Retz, Margitta.Neoadjuvant Therapy Schemes combined with adjuvant Therapy for Patients with muscle invasive Bladder Cancer before or after radical Cystectomy A randomized, open, multicenter, global Phase-III Study to Determine the Efficacy and Safety of Durvalumab in combination with Gemcitabine plus Cisplatin (G plus C) for neoadjuvant Treatment, followed by Durvalumab alone for adjuvant Treatment in Patients with muscle invasive Bladder Cancer ( NIAGARA) - AUO AB 74/20.Aktuelle Urol.2021.52.03.220-221

Koll, Florestan J;Meisenzahl, Eva;Haller, Bernhard;Maisch, Philipp;Kirchhoff, Florian;Horn, Thomas;Gschwend, Jürgen E;Schmid, Sebastian C.Evaluation of Pre-operative Biopsy, Surgical Procedures and Oncologic Outcomes in Upper Tract Urothelial Carcinoma (UTUC)..Front Surg.2021.8

Appleman, Leonard;Todenhoefer, Tilman;Berry, William;Gurney, Howard;Retz, Margitta;Conter, Henry;Laguerre, Brigitte;Fong, Peter;Ferrario, Cristiano;Gravis, Gwenaelle;Piulats, Josep;Emmenegger, Urban;Shore, Neal;Romano, Emanuela;Mourey, Loic;Li, Xin Tong;Poehlein, Christian;Schloss, Charles;De Bono, Johann;Yu, Evan.KEYNOTE-365 COHORT C: PEMBROLIZUMAB plus ENZALUTAMIDE IN PATIENTS WITH ABIRATERONE ACETATE-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)-DATA AFTER MINIMUM OF 22 MONTHS OF FOLLOW-UP.J Immunother Cancer.2021.9 Suppl 2.A374-A374

Gschwend, Juergen E..The Importance of Urine Cytology Reply.Dtsch Arztebl Int.2021.118.31-32.545-545

Meissner, V. H.;Olze, L.;Schiele, S.;Ankerst, D. P.;Jahnen, M.;Gschwend, J. E.;Dinkel, A.;Herkommer, K..Fear of cancer recurrence and disease progression in long-term prostate cancer survivors after radical prostatectomy: A longitudinal study.Eur Urol.2021.79 Suppl 1.S1650-S1650

Tauber, Robert;von Amsberg, Gunhild;De Santis, Maria.[Update on systemic treatment of urothelial cancer: therapy in transition]..Aktuelle Urol.2022.53.2.167-179